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The beneficial role of gastrointestinal endoscopy for
the prevention, diagnosis, and treatment of many diges-
tive diseases and cancer is well established. Like many
sophisticated medical devices, the endoscope is a com-
plex, reusable instrument that requires reprocessing
before being used on subsequent patients. The most com-
monly used methods for reprocessing endoscopes result
in high-level disinfection. To date, all published episodes
of pathogen transmission related to gastrointestinal
endoscopy have been associated with failure to follow
established cleaning and disinfection/sterilization guide-
lines or use of defective equipment. Despite the strong
published data regarding the safety of endoscope repro-
cessing, concern over the potential for pathogen trans-
mission during endoscopy has raised questions about the
best methods for disinfection or sterilization of these
devices between patient uses. To this end, the American
Society for Gastrointestinal Endoscopy (ASGE) and the
Society for Healthcare Epidemiology of America (SHEA)
convened a conference at which representatives from
physician and nursing organizations, infection control
organizations, federal and state agencies, and industry
leaders presented and discussed the latest information on
this subject. A consensus panel on the second day
reviewed the data presented at the conference to recom-
mend evidence-based guidelines for reprocessing gas-
trointestinal endoscopes.
SPAULDING CLASSIFICATION FOR
MEDICAL DEVICES AND LEVEL OF
DISINFECTION
The classification system first proposed by Dr. E. H.
Spaulding divides medical devices into categories based on
the risk of infection involved with their use.1 This classifi-
cation system is widely accepted and is used by the Food
and Drug Administration (FDA), the Centers for Disease
Control and Prevention (CDC), epidemiologists, microbiol-
ogists, and professional medical organizations to help
determine the degree of disinfection or sterilization
required for various medical devices. Three categories of
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medical devices and their associated level of disinfection
are recognized:
• Critical: A device that enters normally sterile tissue
or the vascular system. Such devices should be sterilized,
defined as the destruction of all microbial life. Examples of
endoscopic instruments that require sterilization are biop-
sy forceps and papillotomes.
• Semicritical: A device that comes into contact with
intact mucous membranes and does not ordinarily pene-
trate sterile tissue. These devices (eg, endoscopes) should
receive at least high-level disinfection, defined as the
destruction of all vegetative microorganisms, mycobacte-
ria, small or nonlipid viruses, medium or lipid viruses, fun-
gal spores, and some, but not all, bacterial spores.
• Noncritical: Devices that do not ordinarily touch
the patient or touch only intact skin, such as stethoscopes
or patient carts. These items may be cleaned by low-level
disinfection.
PATHOGEN TRANSMISSION
More than 10 million gastrointestinal endoscopic
procedures are performed annually in the United States.
However, reports of pathogen transmission resulting from
these procedures are rare. In the largest review to date,
comprising 265 scientific articles published between 1966
and 1992, 281 episodes of pathogen transmission were
attributed to gastrointestinal endoscopy.2 In each
instance, pathogen transmission was associated with a
breach in currently accepted cleaning and disinfection
guidelines, use of an unacceptable liquid chemical germi-
cide for disinfection, improper drying, or defective equip-
ment. When the ASGE Technology Assessment
Committee reviewed the 28 cases in that series that had
occurred since the adoption of specific guidelines for
cleaning and disinfection between 1988 and 1992, they
concluded that the incidence of pathogen transmission
was approximately 1 in 1.8 million procedures.3
Since 1993, there have been only five additional
reported cases of pathogen transmission during gastroin-
testinal endoscopy, all occurring outside the United States.
One instance of Trichosporon esophagitis was caused by
failure to sterilize biopsy forceps between patients.4 There
have been four episodes of transmission of hepatitis C virus
(HCV), and each has been associated with a breach in
accepted endoscope reprocessing protocols or a lapse in
general infection control practices (inappropriate use of
multi-dose vials/bottles and/or reuse of syringes).5-7 The
importance of good general infection control practices is
highlighted by a recent outbreak of HCV at a New York
endoscopy center. Although it was initially attributed to
endoscopic transmission in the lay press, investigation by
the New York City Department of Health revealed the
cause was not the endoscopy itself, but related to improper
handling of intravenous sedation tubing or multidose vials
and/or reuse of needles (letter on file, New York City
Department of Health; unpublished data presented at con-
ference). This aspect of standard infection control practice
must also be addressed when future reports of pathogen
transmission are published. When the CDC Division of
Healthcare Quality Promotion (formerly the Hospital
Infection Program) reviewed its log of investigations
between 1980 and 2002, no outbreaks of infection associat-
ed with gastrointestinal endoscopy were found. Since 1990,
healthcare facilities and manufacturers have been required
to report to the FDA any information that reasonably sug-
gests that a device (such as an endoscope, accessory, or
automated endoscope washer–disinfector) has caused or
contributed to a death, injury, or serious illness of a patient.
Review of the FDA Manufacturer And User-Facility Device
Experience (MAUDE) database from 1990 to 2002 revealed
seven possible episodes of pathogen transmission during
gastrointestinal endoscopy. Although there are no well-
designed prospective studies on the incidence of pathogen
transmission during gastrointestinal endoscopy, and esti-
mates of pathogen transmission based on case reports may
underestimate the true incidence of infection, available evi-
dence suggests that this is an extremely rare event.
GASTROINTESTINAL ENDOSCOPE
REPROCESSING
Flexible gastrointestinal endoscopes should first be
cleaned and subjected to at least high-level disinfection. This
standard has been recommended by federal agencies such as
the FDA8 and CDC9; professional organizations such as the
ASGE, the American College of Gastroenterology, the
American Gastroenterology Association, the Society of
Gastroenterology Nurses and Associates, the Association of
Perioperative Registered Nurses, and the Association for
Professionals in Infection Control and Epidemiology; and the
American Society for Testing and Materials.10-13 Guidelines
are available from these organizations that discuss, in a step-
by-step fashion, the elements of appropriate endoscope repro-
cessing.10-14 There are no published studies of transmission of
infection when these guidelines have been followed.
However, compliance with reprocessing guidelines
can be improved. In 1991, Gorse and Messner surveyed
2,030 members of the Society of Gastroenterology Nurses
and Associates and found that compliance with various
aspects of existing guidelines ranged from 67% to 93%.15
That same year, a collaborative study by the FDA and
three state health departments investigating endoscope
reprocessing at 26 healthcare facilities reported that 24%
of patient-ready endoscopes (gastrointestinal endoscopes
and bronchoscopes) were culture positive, and these were
associated with “a number of fundamental errors in the
disinfection process.”16,17 More concerning, Jackson and
Ball surveyed 19 family practice and internal medicine
offices performing flexible sigmoidoscopy and found that
all were deficient in following reprocessing guidelines in
at least one area.18 Although two more recent studies sug-
gest that compliance with reprocessing guidelines has
improved,19,20 a minority of endoscopy centers still did not
conform completely to accepted guidelines. Future
efforts should be aimed at improving compliance with
accepted guidelines in all venues where endoscopy is per-
formed.
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RECOMMENDATIONS (SEE THE APPENDIX
FOR A DESCRIPTION OF CATEGORIES)
Professional organizations vary in recommended
practices. The current document is not intended to replace
these guidelines, but to complement them, emphasizing
those areas in which a broad range of professionals have
reached consensus based on the available evidence.
Endoscopes employing disposable components (eg, pro-
tective barrier devices, sheaths, or valves) can provide an
alternative to conventional liquid chemical disinfection.
Users should refer to manufacturers’ instructions for
appropriate reprocessing.
1. All healthcare personnel in the endoscopy suite
should be trained in and adhere to standard infection con-
trol recommendations (eg, standard precautions), includ-
ing those to protect both patients and healthcare workers.
Category IA9
2. Perform pressure/leak testing after each use
according to manufacturer guidelines. Category IB11-14,21
3. Disconnect and disassemble endoscope compo-
nents (eg, air/water and suction valves) as far as possible
and completely immerse the endoscope and components in
the enzymatic detergent. Category 1B21-23
4. Cleaning is essential prior to manual or automated
disinfection. Meticulously clean the entire endoscope,
including valves, channels, connectors, and all detachable
parts with an enzymatic detergent compatible with the
endoscope immediately after use, according to the manu-
facturer’s instructions. Flush and brush all accessible
channels to remove all organic (eg, blood or tissue) and
other residues. Repeatedly actuate the valves during clean-
ing to facilitate access to all surfaces. Clean the external
surfaces and components of the endoscope using a soft
cloth, a sponge, or brushes. Category IA2,10-14,21,24-33
5. Use brushes appropriate for the size of the endo-
scope channel, parts, connectors, and orifices (eg, bristles
should contact all surfaces) for cleaning. Cleaning items
should be disposable or thoroughly cleaned and disinfect-
ed/sterilized between uses. Category II14,21,28,33
6. Discard enzymatic detergents after each use, as
these products are not microbicidal and will not retard
microbial growth. Category IB12,14,21,23
7. Reusable endoscopic accessories (eg, biopsy for-
ceps or other cutting instruments) that break the mucosal
barrier should be mechanically cleaned as described above
and then sterilized between each patient use (high-level
disinfection is not appropriate). Category IA2,5,9-14,21,26,28,33,34
8. Ultrasonic cleaning of reusable endoscopic acces-
sories and endoscope components may be used to remove soil
and organic material from hard to clean areas. Category II21,33
9. Endoscopes (and accessories) that come in con-
tact with mucous membranes are classified as semicritical
items and should receive at least high-level disinfection
after each patient use. Category IA2,9-12,14,21,26,28,33,35
10. Use a high-level disinfectant/sterilant cleared by
the FDA for high-level disinfection/steriliza-
tion (www.fda.gov/cdrh/ode/germlab.html). Category
IA2,9,10-12,14,21,26,28,35,36
11. The exposure time and temperature for disinfect-
ing semicritical patient care equipment varies among the
FDA-cleared high-level disinfectants. Follow the FDA-
cleared label claim for high-level disinfection unless sever-
al well-designed experimental scientific studies, endorsed
by professional societies, demonstrate an alternative expo-
sure time is effective for disinfecting semicritical items.
The FDA label claim for high-level disinfection with greater
than 2% glutaraldehyde at 25°C ranges from 20 to 90 min-
utes depending on the product. However, multiple scientif-
ic studies and professional organizations support the effi-
cacy of greater than 2% glutaraldehyde at 20 minutes at
20°C. Category IA1,10,21,26,27,32,37-49
12. Select a disinfectant/sterilant that is compatible
with the endoscope. The use of specific high-level disinfec-
tants/sterilants on an endoscope should be avoided if the
endoscope manufacturer warns against use because of
functional damage (with or without cosmetic damage).
Category IB21,50,51
13. The selection and use of disinfectants in the
healthcare field is dynamic, and products may become
available that were not in existence when this guideline was
written. As newer disinfectants become available, persons
or committees responsible for selecting disinfectants for
gastrointestinal endoscope reprocessing should be guided
by products cleared by the FDA and information in the sci-
entific literature. Category II21,26,36
14. Completely immerse the endoscope and its com-
ponents in the high-level disinfectant/sterilant and ensure
that all channels are perfused. Nonimmersible gastroin-
testinal endoscopes should be phased out immediately.
Category IB10,11,13,14,21,26,28,52-54
15. If an automated endoscope washer–disinfector
(AEWD) is used, ensure that the endoscope and endo-
scope components can be effectively reprocessed in the
AEWD (eg, the elevator wire channel of duodenoscopes is
not effectively disinfected by most AEWDs and this step
must be performed manually). Users should obtain and
review model-specific reprocessing protocols from both the
endoscope and the AEWD manufacturers and check for
compatibility. Category IB10,12,14,21,28,52-56
16. If an AEWD is used, place the endoscope and
endoscope components in the reprocessor and attach all
channel connectors according to the AEWD and endo-
scope manufacturers’ instructions to ensure exposure of all
internal surfaces with the high-level disinfectant/chemical
sterilant. Category IB14,21,52-54
17. If an AEWD cycle is interrupted, high-level disin-
fection or sterilization cannot be ensured. Category II14
18. Because design flaws have compromised the
effectiveness of AEWDs, the infection control staff should
routinely review FDA advisories, manufacturer alerts, and
the scientific literature for reports of AEWD deficiencies
that may lead to infection. Category II53,57-60
19. After high-level disinfection, rinse the endoscope
and flush the channels with sterile, filtered, or tap water to
remove the disinfectant/sterilant. Discard the rinse water
after each use/cycle. Flush the channels with 70% to 90%
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ethyl or isopropyl alcohol and dry using forced air. The
final drying steps greatly reduce the possibility of reconta-
mination of the endoscope by waterborne microorganisms.
Category IA10-13,21,26,30,58,61-63
20. When storing the endoscope, hang it in a vertical
position to facilitate drying (with caps, valves, and other
detachable components removed as per manufacturer
instructions). Category II11,12,14,21,26,28,64
21. Endoscopes should be stored in a manner that
will protect them from contamination. Category II11,14,21,26,28
22. High-level disinfect or sterilize the water bottle
(used for cleaning the lens and irrigation during the proce-
dure) and its connecting tube at least daily. Sterile water
should be used to fill the water bottle. Category IB11,21,65-68
23. Maintain a log indicating for each procedure the
patient’s name and medical record number (if available),
the procedure, the endoscopist, and the serial number or
other identifier of the endoscope (and AEWD, if used) to
assist in an outbreak investigation. Category II11,14,21
24. Perform routine testing of the liquid
sterilant/high-level disinfectant to ensure minimal effective
concentration of the active ingredient. Check the solution
at the beginning of each day of use (or more frequently)
and document the results. If the chemical indicator shows
that the concentration is less than the minimal effective
concentration, the solution should be discarded. Category
IA10-12,14,21,26,35,42
25. Discard the liquid sterilant/high-level disinfec-
tant at the end of its reuse life (which may be single-use),
regardless of the minimal effective concentration. If addi-
tional liquid sterilant/high-level disinfectant is added to an
AEWD (or basin, if manually disinfected), the reuse life
should be determined by the first use/activation of the
original solution (ie, the practice of “topping off” of a liquid
sterilant/high-level disinfectant pool does not extend its
reuse life). Category IB14,26,69
26. Facilities where endoscopes are used and disin-
fected should be designed to provide a safe environment
for healthcare workers and patients. Air-exchange equip-
ment (eg, ventilation system and exhaust hoods) should be
used to minimize the exposure of all persons to potentially
toxic vapors (eg, glutaraldehyde). The vapor concentration
of the chemical sterilant used should not exceed allowable
limits (eg, those of the American Conference of
Governmental Industrial Hygienists and the Occupational
Safety and Health Administration). Although organic vapor
respirators appropriate for chemical exposures can provide
respiratory protection (eg, in the event of spills), they are
not intended for routine use and are not a substitute for
adequate ventilation, vapor recovery systems, and work
practice controls. Category IB and IC10,11,14,21,70-73
27. Personnel assigned to reprocess endoscopes
should receive device-specific reprocessing instructions
(ie, endoscope and/or AEWD manufacturer, as needed) to
ensure proper cleaning and high-level disinfection or steril-
ization. Competency testing of personnel reprocessing
endoscopes should be done on a regular basis (eg, com-
mencement of employment, annually). Temporary person-
nel should not be allowed to reprocess endoscopes until
competency has been established. Category IA10-12,14,21
28. All personnel using chemicals should be educat-
ed about the biological and chemical hazards present while
performing procedures that use disinfectants. Category
IC21,74
29. Personal protective equipment (eg, gloves,
gowns, eyewear, and respiratory protection devices)
should be readily available and should be used, as appro-
priate, to protect workers from exposure to chemicals,
blood, or other potentially infectious material. Category
IC21,74-76
30. Healthcare facilities should develop protocols to
ensure that users can readily identify whether an endo-
scope is contaminated or is ready for patient use. Category
II
31. The use of routine environmental microbiologic
testing of endoscopes for quality assurance has not been
established. No recommendation.21
32. If environmental microbiologic testing is per-
formed, standard microbiologic techniques should be
used. Category II21,77
33. In the setting of an outbreak caused by a sus-
pected infectious or chemical etiology, the environmental
sampling should be performed according to standard out-
break investigation. Category 1A11,21,78
34. Endoscopy-related infections should be reported
to:
a) Persons responsible for infection control at the
institution.
b) The appropriate public health agency (state or
local health department as required by state law or regula-
tion).
c) The FDA (www.fda.gov/medwatch).
d) The CDC.
e) The manufacturer(s) of the endoscope, disinfec-
tant/sterilant, and AEWD (if used) Category IB and
IC10,11,21,79
SUMMARY
Flexible gastrointestinal endoscopy is a valuable
diagnostic and therapeutic tool for the care of patients with
gastrointestinal and pancreaticobiliary disorders.
Compliance with accepted guidelines for the reprocessing
of gastrointestinal endoscopes between patients is critical
to the safety and success of their use. When these guide-
lines are followed, pathogen transmission can be effective-
ly prevented. Increased efforts and resources should be
directed to improve compliance with these guidelines.
Further research in the area of gastrointestinal endoscope
reprocessing should be encouraged. The organizations
that endorsed this guideline are committed to assisting the
FDA and manufacturers in addressing critical infection
control issues in gastrointestinal device reprocessing.
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APPENDIX
The Centers for Disease Control and Prevention sys-
tem for categorizing recommendations is as follows:
Category IA. Strongly recommended for implementa-
tion and strongly supported by well-designed experimental,
clinical, or epidemiologic studies.
Category IB. Strongly recommended for implementa-
tion and supported by some experimental, clinical, or epi-
demiologic studies and a strong theoretical rationale.
Category IC. Required by state or federal regulations.
Because of state differences, readers should not assume
that the absence of an IC recommendation implies the
absence of state regulations.
Category II. Recommended for implementation and
supported by suggestive clinical or epidemiologic studies
or theoretical rationale.
No recommendation. Unresolved issue. Practices for
which insufficient evidence or no consensus regarding effi-
cacy exists.
